Digital innovation in clinical trials

Strategic implications for drug and device development

Watch the event recording

 

Digital innovation has had a significant impact on the life sciences industry over the past two years. Remote monitoring tools have transformed clinical development with promises of increased trial quality, greater efficiency and stronger patient engagement – all at a lower cost. At the same time, these new tools introduce regulatory and clinical challenges, requiring drug/device developers as well as regulators to adapt and transform to keep pace with the rapidly changing environment.

Listen to our podcast series below where our expert panel tackles pressing questions on digital innovation and its implications on clinical trials.

Defining digital innovation

Our expert panel featuring Dr. Scott Gottlieb, former commissioner of the U.S. Food and Drug Administration (FDA), Shwen Gwee, VP and Head of Global Digital Strategy at Bristol Myers Squibb, and Joel Haspel, SVP Strategy, Science Group at Clarivate take a look at how clinical development can be viewed through the lens of digital innovation.

Accelerating digital tools in compliance with regulatory guidelines

Our expert panel featuring Dr. Scott Gottlieb, former commissioner of the U.S. Food and Drug Administration (FDA), Shwen Gwee, VP and Head of Global Digital Strategy at Bristol Myers Squibb, and Joel Haspel, SVP Strategy, Science Group at Clarivate take a closer look at accelerating the use of digital tools in compliance with regulatory guidelines.

How COVID-19 is changing the way the industry is looking at digital health’s future

Our expert panel featuring Dr. Scott Gottlieb, former commissioner of the U.S. Food and Drug Administration (FDA), Shwen Gwee, VP and Head of Global Digital Strategy at Bristol Myers Squibb, and Joel Haspel, SVP Strategy, Science Group at Clarivate take a look at how COVID-19 is changing the way industry is looking at the future of digital health.